ZYME · Zymeworks Inc. · Executive Compensation
$28.37
+0.15 (+0.53%)
At close · Oct 26
Return incl. dividend (before tax)
Market Cap
$1.99B
Shares
70.96M
Volume · Oct 26
833.97K
Avg daily vol (3M)
881.53K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Kenneth Galbraith | CEO, President & Chair | $6,613,180 |
| Paul A. Moore | CSO | $2,348,190 |
| Jeffrey Smith | Former Chief Medical Officer | $2,050,798 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kenneth Galbraith | CEO, President & Chair | $5,492,157 |
| Leone Patterson | Exec. VP, Chief Business Officer & CFO | $2,907,982 |
| Paul Moore | CSO | $1,986,803 |
| Paul A. Moore | CSO | $1,986,803 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kenneth Galbraith | Chair, President & CEO | $3,374,876 |
| Neil Klompas | Former President & COO | $2,125,732 |
| Paul Moore | CSO | $1,682,237 |
| Christopher Astle | Former SVP & CFO | $1,191,820 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kenneth Galbraith | Chair, President & CEO | $7,125,457 |
| Neil Klompas | Former President & COO | $1,808,408 |
| Christopher Astle | Former SVP & CFO | $1,315,005 |
| Ali Tehrani | Former President & CEO ^ ^ | $964,243 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ali Tehrani | Former President & CEO ^ ^ | $5,110,637 |
| Neil Josephson | Chief Medical Officer | $3,547,690 |
| Anthony Polverino | Former Executive VP, Early Development & Chief ScientificOfficer | $1,917,908 |
| Neil Klompas | Former President & COO ^ ^ | $1,900,478 |
| Diana Hausman | Former Chief Medical Officer | $1,646,089 |
| James Priour | Former Chief Commercial Officer | $1,541,343 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ali Tehrani | Former President & CEO | $4,877,459 |
| Diana Hausman | Former Chief Medical Officer | $1,933,847 |
| Anthony Polverino | Former Executive VP, Early Development & Chief ScientificOfficer | $1,903,941 |
| Neil Klompas | President and Chief Operating Officer (former CFO) | $1,887,097 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Ali Tehrani | Former President & CEO | $3,278,069 |
| Neil Klompas | President and Chief Operating Officer (former CFO) | $1,624,174 |
| Diana Hausman | Former Chief Medical Officer | $1,404,525 |
| Anthony Polverino | Former Executive VP, Early Development & Chief ScientificOfficer | $1,336,403 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kristin Stafford | Executive Vice President, Chief Financial Officer | Appointed | 2026-04-01 |
| Sabeen Mekan | Senior Vice President and Chief Medical Officer | Appointed | 2026-01-12 |
| Mark Hollywood | Executive Vice President and Chief Operating Officer | Appointed | 2026-01-12 |
| Jeffrey Smith | Executive Vice President and Chief Medical Officer | Retired | 2026-01-12 |
| Kenneth Galbraith | interim Chief Financial Officer | Appointed | 2026-01-12 |
| Leone Patterson | Executive Vice President, Chief Business Officer and Chief Financial Officer | Terminated | 2026-01-12 |
| Brian Cherry | Class II director | Appointed | 2026-01-12 |
| Scott Platshon | Acting Chief Investment Officer | Appointed | 2025-11-18 |
| Scott Platshon | board of directors | Resigned | 2025-11-18 |
| Greg Ciongoli | Board of Directors | Appointed | 2025-08-11 |
| Troy M. Cox | Board | Resigned | 2025-08-11 |
| Robert E. Landry | director of the Company | Appointed | 2025-08-11 |
| Gregory A. Ciongoli | director of the Company | Appointed | 2025-08-11 |
| Scott Platshon | Compensation Committee member | Appointed | 2025-02-18 |
| Oleg Nodelman | director | Appointed | 2025-02-18 |
| Neil Gallagher | member of the Board's compensation committee | Appointed | 2024-10-18 |
| Susan Mahony | chair of the Board's compensation committee | Appointed | 2024-10-18 |
| Kenneth Galbraith | interim Chief Financial Officer and as principal financial officer and principal accounting officer | Resigned | 2024-09-03 |
| Leone Patterson | Executive Vice President, Chief Business Officer and Chief Financial Officer | Appointed | 2024-09-03 |
| Leone Patterson | Executive Vice President, and Chief Business and Financial Officer | Appointed | 2024-07-25 |
| Kenneth Galbraith | interim Chief Financial Officer | Resigned | 2024-07-25 |
| Leone Patterson | Executive Vice President, Chief Business Officer and Chief Financial Officer | Appointed | 2024-07-25 |
| Dr. Christopher Astle | Senior Vice President and Chief Financial Officer, including as the Company's principal financial officer and principal accounti | Terminated | 2024-04-04 |
| Kenneth Galbraith | interim Chief Financial Officer | Appointed | 2024-04-01 |
| Christopher Astle | Senior Vice President and Chief Financial Officer, including as the Company's principal financial officer and principal accounti | Terminated | 2024-04-01 |
Leadership
- Ali Tehrani CEO
- Kenneth Galbraith CEO, CFO
- Kristin Stafford CFO
- Leone Patterson CFO
- Mark Hollywood COO
- Scott Platshon CIO, Board Member
- Paul Schneider General Counsel
- Alessandra Cesano Board Member
- Brian Cherry Board Member
- Carlos Campoy Board Member
- Derek Miller Board Member
- Dr. Alessandra Cesano Board Member
- Dr. Neil Gallagher Board Member
- Greg Ciongoli Board Member
- Gregory A. Ciongoli Board Member
- Neil Gallagher Board Member
- Oleg Nodelman Board Member
- Robert E. Landry Board Member
Key facts
CIK
1937653
CUSIP
98985Y108
13F (30d)
24 filings
24 filers
Visit website
Investor relations